{"id":"W4399285742","doi":"10.1038/s41591-024-02986-9","title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","year":2024,"lang":"en","type":"article","venue":"Nature Medicine","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":130,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"Loxo Oncology; Pharmacyclics; Chugai Pharmaceutical; Genentech; EMD Serono; MorphoSys; SymBio Pharmaceuticals Limited; BeiGene; Mitsubishi Tanabe Pharma Corporation; Seagen; Celgene; Alimera Sciences; Eisai; Astellas Pharma; Adaptive Biotechnologies; Pfizer; Incyte; TG Therapeutics; bluebird bio; Daiichi Sankyo Europe; National Cancer Institute; Gilead Sciences; Calithera Biosciences; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Alexion Pharmaceuticals; Karyopharm Therapeutics; Sanofi; Amgen; AstraZeneca; Ono Pharmaceutical; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Follicular phase; Lymphoma; Oncology; Confidence interval; Rituximab; CD20; Clinical endpoint; Gastroenterology; Clinical trial; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001969366,0.000799712,0.0009612454,0.0003596099,0.0001822919,0.0006594572,0.0007181455,0.0008637037,0.003136626],"category_scores_gemma":[0.0008489398,0.0002368653,0.001127708,0.0002296148,0.0003450441,0.0005854342,0.0003768408,0.001643259,0.000737482],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005470701,"about_ca_system_score_gemma":0.0006756371,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004296823,"about_ca_topic_score_gemma":0.001192761,"domain_scores_codex":[0.9996237,0.0002020516,0.00001434885,0.00004113918,0.00006339667,0.00005547038],"domain_scores_gemma":[0.9995487,0.00008673385,0.0001053938,0.00004174478,0.00005380181,0.0001634098],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4650193,0.04618218,0.01515615,0.002781554,0.003194351,0.0005028152,0.0003872612,0.002948661,0.04437198,0.001011834,0.0164681,0.4019759],"study_design_scores_gemma":[0.4868481,0.4387142,0.03190991,0.0002614102,0.00211357,0.0008791892,0.0001323514,0.001984034,0.007805869,0.0006386988,0.02865268,0.00006003084],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9668322,0.01761303,0.001015385,0.001229081,0.0002123813,0.00305601,0.002415229,0.0002025264,0.007424158],"genre_scores_gemma":[0.9746357,0.006914431,0.002196393,0.002222805,0.000318483,0.003000418,0.005351493,0.00005338158,0.005306989],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003136626,"threshold_uncertainty_score":0.0104931,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0222716939987892,"score_gpt":0.3854360734110371,"score_spread":0.3631643794122479,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}